Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination

Vaccine

Volumn 25, Issue 47, 2007, Pages 8085-8090

  Su, Fu Hsiung ^a,b   Cheng, Shu Hsing ^c,d   Li, Chung Yi ^e   Chen, Jong Dar ^f   Hsiao, Chih Yin ^a   Chien, Chih Ching ^b   Yang, Ya Chuan ^b   Hung, Hsiu Hsing ^b   Chu, Fang Yeh ^a,g  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c Public Health Bureau   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^f SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^g YUANPEI UNIVERSITY   (Taiwan)

Author keywords

Booster dose; Hepatitis B antibodies; Hepatitis B vaccination; Taiwan

Indexed keywords

HAVAC B; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SEROPREVALENCE; TAIWAN; TREATMENT RESPONSE; UNIVERSITY STUDENT; VACCINATION; VIRUS CARRIER; VIRUS TITRATION;

ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; SEROEPIDEMIOLOGIC STUDIES; TAIWAN; TIME FACTORS;

EID: 35448997829     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.013     Document Type: Article

References (42)

1. Merican I., Guan R., Amarapuka D., Alexander M.J., Chutaputti A., Chien R.N., et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15 (2000) 1356-1361
2. World Health Organization. Hepatitis B. Geneva: WHO/CDS/CSR/LYO/2002.2: hepatitis B:54; 2002.
3. Beasley R.P. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiological considerations. Hepatology 2 (1982) 21S-26S
4. Beasley R.P., Hwang L.Y., Lin C.C., and Chen C.S. Hepatocellular carcinoma and hepatitis B virus: a perspective study of 22707 men in Taiwan. Lancet 2 (1981) 1129-1133
5. Chen D.S. Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: Okuda K., and Ishak K.G. (Eds). Neoplasms of the liver (1987), Springer-Verlag Inc., Tokyo, Japan 71-80
6. Chen D.S., and Sung J.L. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol 25 (1978) 423-430
7. Wu J.S., Chen C.H., Chiang Y.H., Lee Y.C., Lee M.H., Ko Y.C., et al. Hepatitis B virus infection in Taiwan with reference to anti-HBc versus HBsAg and anti-HBs. J Formosan Med Assoc 79 (1980) 760-767
8. Sung J.L., Chen D.S., Lai M.Y., Yu J.Y., Wang T.H., Wang C.Y., et al. Epidemiological study of hepatitis B virus infection in Taiwan. Chin J Gastroenterol 1 (1984) 1-9
9. Department of Health. Health and vital statistics. Republic of China: Department of Health, Executive Yuan; 2006.
10. Chuang C.H. Hepatitis B control program in Taiwan. Acta Paediatr Jpn 31 (1989) 645-648
11. Wong W.C., and Tsang K.K. A mass hepatitis B vaccination programme in Taiwan: its preparation, results and reasons for uncompleted vaccinations. Vaccine 12 (1994) 229-234
12. Chen H.L., Chang M.H., Ni Y.H., Hsu N.Y., Lee P.I., Lee C.Y., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276 (1996) 906-908
13. Hsu H.Y., Chang M.H., Liaw S.H., Ni Y.H., and Chen H.L. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30 (1999) 1312-1317
14. Hsu H.Y., Chang M.H., Chen D.S., Lee C.Y., and Sung J.L. Baseline seroepidemiology of hepatitis B virus infection in Taipei, 1984: a study just before a mass hepatitis B vaccination program in Taiwan. J Med Virol 18 (1986) 301-307
15. Tsen Y.J., Chang M.H., Hsu H.Y., Lee C.Y., Sung J.L., and Chen D.S. Seroprevalence of hepatitis B infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol 34 (1991) 96-99
16. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
17. Ni Y.H., Chang M.H., Huang L.M., Chen H.L., Hsu H.Y., Chiu T.Y., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area:15 years after mass hepatitis B vaccination. Ann Intern Med 135 (2001) 796-800
18. Lin H.H., Wang L.Y., Hu C.T., Huang S.C., Huang L.C., Lin S.S., et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 69 (2003) 471-474
19. Su F.H., Chen J.D., Cheng S.H., Lin C.H., Liu Y.H., and Chu F.Y. Seroprevalence of hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national hepatitis-B vaccination program. J Med Virol 79 (2007) 128-143
20. Petersen K.M., Bulkow L.R., McMahon B.J., Zanis C., Getty M., Peters H., et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 23 (2004) 650-655
21. Lok A.S., Lai C.L., and Wu P.C. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 8 (1988) 766-770
22. Chan C.Y., Lee S.D., Tsai Y.T., and Lo K.J. Hepatitis B vaccination alone is not adequate for the categorizing of adult subjects with isolated anti-HBc. J Gastroenterol Hepatol 10 (1995) 192-197
23. Lu S.N., Chen C.H., Chen T.M., Le P.L., Wang J.H., Tung H.D., et al. Hepatitis B virus infection in adolescents in a rural township-15 years subsequent to mass hepatitis B vaccination in Taiwan. Vaccine 24 (2006) 759-765
24. Coursaget P., Yvonnet B., Gilks W.R., Wang C.C., Day N.E., Chiron J.P., et al. Scheduling of revaccination against hepatitis B virus. Lancet 337 (1991) 1180-1183
25. Gesemann M., and Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13 (1995) 443-447
26. Fujisawa T., Onoue M., Inui A., and Kosugi T. Serial changes in titers of antibody to hepatitis B surface antigen after immunization of infants born to mothers with hepatitis B e antigen. J Pediatr Gastroenterol Nutr 23 (1996) 270-274
27. Huang L.M., Chiang B.L., Lee C.Y., Lee P.I., Chi W.K., and Chang M.H. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 29 (1999) 954-959
28. van der Sande M.A.B., Waight P., Mendy M., Rayco-solon P., Hutt P., Fulford T., et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 193 (2006) 1528-1535
29. Jilg W., Schmidt M., and Deinhardt F. Immune response to hepatitis B revaccination. J Med Virol 24 (1988) 377-384
30. Wismans P.J., Van Hattum J., Mudde G.C., Endeman H.J., Poel J., and de Gast G.C. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 8 (1989) 236-240
31. Coursaget P., Leboulleux D., Soumare M., le Cann P., Yvonnet B., Chiron J.P., et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 21 (1994) 250-254
32. Da Villa G., Peluso F., Picciotto L., Bencivenga M., Elia S., and Pelliccia M.G. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 14 (1996) 1503-1505
33. Resti M., Azzari C., Mannelli F., Rossi M.E., Lionetti P., and Vierucci A. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?. Vaccine 15 (1997) 1338-1340
34. European Consensus Group on Hepatitis B immunity. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5.
35. Young B.W., Lee S.S., Lim W.L., and Yeoh E.K. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 10 (2003) 23-30
36. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 22 (2004) 607-610
37. Lu C.Y., Chiang B.L., Chi W.K., Chang M.H., Ni Y.H., Hsu H.M., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40 (2004) 1415-1420
38. Yuen M.F., Lim W.L., Chan A.O., Wong D.K., Sum S.S., and Lai C.L. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2 (2004) 941-945
39. Dentinger C.M., McMahon B.J., Butler J.C., Dunaway C.E., Zanis C.L., Bulkow L.R., et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 24 (2005) 786-792
40. Shih H.H., Chang M.H., Hsu H.Y., Lee P.I., Ni Y.H., and Chen D.S. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatr Infect Dis J 18 (1999) 427-432
41. Zuckerman J.N. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 50 (1996) 283-288
42. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 (2002) 3644-3649